I Diretriz Latino-Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica

Castro, Iran; Andrade, Jadelson Pinheiro de; Vilas-Boas, Fábio; Neto, J A Marin; Chagas, Antônio Carlos Palandri; Rocha, Eduardo; Oliveira, Gláucia Maria Moraes de; Zimerman, Leandro Ioschpe; Campos, Luiz Antonio de Almeida; Montera, Marcelo Westerlund; Barbosa, Márcia de Melo; Guimarães, Jorge Ilha; Morillo, Carlos A.; Acquatella, Harry; Mitelman, Jorge; Moreno, Juan Bautista Gonzalez; Giménez, Luisa; Dones, Wistremundo; Filho, Abílio Augusto Fragata; Paola, Ângelo Amato Vincenzo de; Almeida, Dirceu Rodrigues; Bocchi, Edimar Alcides; Bacal, Fernando; Dias, João Carlos Pinto; Moreira, Maria da Consolação Vieira; Xavier, Sérgio Salles; Oliveira, Wilson Alves de

doi:10.1590/s0066-782x2011001600001

Cited by 77 publications

(33 citation statements)

References 297 publications

(485 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for other complementary tests, these may be ordered according to the specific labor activities that the individual will perform. Similarly, in these cases, temporary or permanent removal from work activity is not recommended (192) (200) (201) (202) (203) . Engaging in usual, regular physical activity is not contraindicated in patients with ICF.…”

Section: Treatment and Clinical Follow-upmentioning

confidence: 99%

“…If immunodeficiency (acquired or induced) occurs in patients with ICF, special attention should be given to possible reactivation of Chagas disease (see specific section on reactivation of Chagas disease) (20) (49) (159) . The surgical risk for the patient with ICF does not differ from that observed in the general, uninfected population (20) (194) (200) (202) (203) .…”

Section: Treatment and Clinical Follow-upmentioning

confidence: 99%

“…Treatment Pharmacological management of acute Chagas myocarditis is even recommended for the treatment of heart failure in patients with acute myocarditis of other etiologies: Routine use nd Brazilian Consensus on Chagas Disease, 2015 (203) .…”

Section: Laboratory and Radiologic Examinationsmentioning

confidence: 99%

“…In addition to the fact that there are no controlled studies exploring in a scientific and valid manner this therapeutic possibility, in CCC the complete block of the right bundle branch is frequent and, in the presence of this condition, evidence of the benefits of CRT, even in other etiologies of heart failure, are even more scarce and less convincing (203) (244) .…”

Section: Complementary Forms Of Treatment For Heart Failure Caused Bymentioning

confidence: 99%

See 3 more Smart Citations

2 nd Brazilian Consensus on Chagas Disease, 2015

Dias

Ramos

Gontijo

et al. 2016

Rev. Soc. Bras. Med. Trop.

Self Cite

278

449

View full text Add to dashboard Cite

Section: Treatment and Clinical Follow-upmentioning

confidence: 99%

Section: Treatment and Clinical Follow-upmentioning

confidence: 99%

Section: Laboratory and Radiologic Examinationsmentioning

confidence: 99%

Section: Complementary Forms Of Treatment For Heart Failure Caused Bymentioning

confidence: 99%

See 2 more Smart Citations

2 nd Brazilian Consensus on Chagas Disease, 2015

Dias

Ramos

Gontijo

et al. 2016

Rev. Soc. Bras. Med. Trop.

Self Cite

278

449

View full text Add to dashboard Cite

“…The main symptomatic form of Chagas disease is a cardiomyopathy characterized by heart failure, ventricular arrhythmias, heart blocks, thromboembolic events and sudden death [1]. Previous studies demonstrated that subjects with Chagas disease cardiomyopathy have worse long-term outcomes than subjects with cardiomyopathy due to other etiologies [2].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Galectin-3 as a Novel Biomarker for Chagas Cardiomyopathy

Noya-Rabelo

Larocca²,

Torreão³

et al. 2016

Cardiology

View full text Add to dashboard Cite

Objectives: Chagas cardiomyopathy has worse long-term outcomes than other cardiomyopathies. A biomarker strategy to refer subjects for noninvasive cardiac imaging may help in the early identification of cardiac damage in subjects with Chagas disease. Galectin-3 (Gal-3) is a mediator of cardiac fibrosis shown to be upregulated in animal models of decompensated heart failure. Here we assessed the correlation of Gal-3 with myocardial fibrosis in patients with Chagas disease. Methods: This study comprised 61 subjects with Chagas disease. All subjects underwent clinical assessments, Doppler echocardiography and magnetic resonance imaging. Plasmatic Gal-3 was determined by ELISA. Results: Delayed enhancement (DE) was identified in 37 of 61 subjects (64%). The total amount of myocardial fibrosis was 9.4% [interquartile interval (IQI): 2.4-18.4]. No differences were observed in Gal-3 concentration according to the presence or absence of myocardial fibrosis, with a median Gal-3 concentration of 11.7 ng/ml (IQI: 9.4-15) in subjects with DE versus 12.9 ng/ml (IQI: 9.2-14) in subjects without DE (p = 0.18). No correlation was found between myocardial fibrosis and Gal-3 concentration (r = 0.098; p = 0.47). Conclusions: There is no correlation between the degree of myocardial fibrosis and the concentration of Gal-3 in subjects with Chagas disease.

show abstract

Heart failure: preventing disease and death worldwide

et al. 2014

View full text Add to dashboard Cite

Executive Summary Heart failure is a life-threatening disease and addressing it should be considered a global health priority. At present, approximately 26 million people worldwide are living with heart failure. The outlook for such patients is poor, with survival rates worse than those for bowel, breast or prostate cancer. Furthermore, heart failure places great stresses on patients, caregivers and healthcare systems. Demands on healthcare services, in particular, are predicted to increase dramatically over the next decade as patient numbers rise owing to ageing populations, detrimental lifestyle changes and improved survival of those who go on to develop heart failure as the final stage of another disease. It is time to ease the strain on healthcare systems through clear policy initiatives that prioritize heart failure prevention and champion equity of care for all. Despite the burdens that heart failure imposes on society, awareness of the disease is poor. As a result, many premature deaths occur. This is in spite of the fact that most types of heart failure are preventable and that a healthy lifestyle can reduce risk. Even after heart failure has developed, premature deaths could be prevented if people were taught to recognize the symptoms and seek immediate medical attention. Public awareness campaigns focusing on these messages have great potential to improve outcomes for patients with heart failure and ultimately to save lives.

show abstract

I Diretriz Latino-Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica

Cited by 77 publications

References 297 publications

2 nd Brazilian Consensus on Chagas Disease, 2015

2 nd Brazilian Consensus on Chagas Disease, 2015

Evaluation of Galectin-3 as a Novel Biomarker for Chagas Cardiomyopathy

Heart failure: preventing disease and death worldwide

Contact Info

Product

Resources

About